FDA approves new version of Novartis' Zolgensma Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 25 November, 2025

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Save $200 with Early Bird rates — reserve your spot today.

presented by Start smarter, dis­cov­er faster: EM­Ly Co-pi­lot, an AI-dri­ven bi­o­log­ics dis­cov­ery plat­form

news Novartis was the sole bidder in $12B deal to buy Avidity Novartis to reach older spinal muscular atrophy patients as FDA approves new version of Zolgensma UK-US drug pricing deal could come as early as this week, sources say #ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 wins

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine Dec 09 11:00am ET Strategic solutions for cost, time and quality challenges in drug development sponsored by Cambrex Dec 16 11:30am ET Maintaining EU GMP Annex I expectations while adopting new standards for prefilled syringe systems sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

Our latest survey captured the bleakest biotech outlook in a decade — but is recent momentum real or a mirage? Join us to hear what CEOs are saying about the industry’s direction. Sign up now.

in case you missed it 1. FDA's Pazdur questions legality of voucher program, sources say, in latest internal disagreement 2. J&J’s tau-targeting antibody fails Phase 2 Alzheimer's study 3. Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials 4. Updated: Kelun's TROP2 ADC plus Keytruda improved outcomes in lung cancer study 5. News Briefing Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis data 6. Exclusive: Craig Crews, Mikael Dolsten get $32M for Quarry Thera, with plans for more biotechs 7. Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win 8. Nobel laureate Carolyn Bertozzi to rejoin Lilly board